Drugs that contain Aprepitant
1. Aponvie patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9808465 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9561229 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US10500208 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9974793 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US10624850 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US9974742 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US11173118 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US10953018 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9974794 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US11744800 | HERON THERAPS INC | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
Sep, 2035
(11 years from now) | |
Market Authorisation Date: 16 September, 2022
Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting; A method for preventing of post-operative nausea and vomiting
Dosage: EMULSION;INTRAVENOUS
APONVIE family patents
2. Cinvanti patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561229 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US10624850 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US9974742 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US9974793 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9974794 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US11173118 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US10500208 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US11744800 | HERON THERAPS INC | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
Sep, 2035
(11 years from now) | |
| US10953018 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9808465 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
Market Authorisation Date: 09 November, 2017
Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy
Dosage: EMULSION;INTRAVENOUS
CINVANTI family patents
3. Emend patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5719147 | MERCK | Morpholine and thiomorpholine tachykinin receptor antagonists |
Apr, 2015
(9 years ago) | |
| US6096742 | MERCK | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214692 | MERCK | Medical use for tachykinin antagonists |
Sep, 2012
(11 years ago) | |
| US5538982 | MERCK | Medical use for tachykinin antagonists |
Jul, 2013
(10 years ago) | |
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 28, 2018 |
| M(M-82) | Mar 19, 2013 |
Market Authorisation Date: 30 June, 2006
Treatment: Treatment or prevention of emesis; Prevention of postoperative nausea and vomiting; Prevention of post-operative nausea and vomiting
Dosage: CAPSULE;ORAL
EMEND family patents
4. Emend patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6096742 | MSD MERCK CO | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 28, 2018 |
Market Authorisation Date: 17 December, 2015
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
Dosage: FOR SUSPENSION;ORAL
EMEND family patents